BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221018
DTEND;VALUE=DATE:20221021
DTSTAMP:20260515T234014
CREATED:20220620T112738Z
LAST-MODIFIED:20220620T112738Z
UID:34479-1666051200-1666310399@www.pharmajournalist.com
SUMMARY:Process Development for Cell Therapies Summit
DESCRIPTION:“The Process is the Product” – Drive Process Excellence at the Only Summit Dedicated to Process Development for Cell Therapies \n \nAs momentum continues to build for the cell therapy industry\, process development looms as a huge potential bottleneck to overcome. The inaugural Process Development for Cell Therapies Summit will give you unprecedented access to an industry melting pot of process development tools and experience to drive down cost of goods\, maximize scalability and achieve regulatory compliance. \nJoin your peers who will all be gathering to learn how to identify and plug platform gaps for automation\, global scale-out\, faster phase development\, increased affordability\, and more! \nWith 20+ case studies being presented\, you will come away with tried and tested strategies informed by industry leaders such as BMS\, Kite\, Lyell Immunopharma\, and Immatics Biotechnologies. There is no other event of this kind which is focused specifically on Process Development for Cell Therapy\, delivering case studies to provide actionable insights. \nNow is the time to gather with the industry gurus to unpick shared challenges in process development and share best practices to de-silo the industry and bring better therapies to patients faster. \nFind out more about the meeting\, who’s attending and what you could learn by downloading the latest event guide: https://ter.li/lbtpp0 \nWe look forward to welcoming you to Boston in October!
URL:https://www.pharmajournalist.com/event/process-development-for-cell-therapies-summit/
LOCATION:Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221018
DTEND;VALUE=DATE:20221021
DTSTAMP:20260515T234014
CREATED:20220622T094513Z
LAST-MODIFIED:20220622T094513Z
UID:34491-1666051200-1666310399@www.pharmajournalist.com
SUMMARY:3rd Annual Gene Therapy Immunogenicity Summit
DESCRIPTION:The 3rd Annual Gene Therapy Immunogenicity Summit is industry’s definitive forum enabling you to better modulate\, measure and predict the immune response to your gene therapy candidate. \nIn the context of ever-increasing gene therapy clinical activity and uncertainty around challenges posed by immune responses to delivery\, this summit will unite large pharma and innovative biotech’s to ensure that you’re up to speed on the latest approaches to evaluate and overcome pre-existing immunity to AAV vectors\, understand how immune-modulatory strategies can help to ensure efficacy and safety and learn the reality of regulatory expectations around immunological assays. \nIncorporating insights from leading immunological\, bioanalytical\, and translational experts\, this is your opportunity to gain extensive technical information on the contrasts between immunogenicity encountered across organs and administration routes\, how models can be enhanced to enable comparative immunology between species and what the latest clinical data tells us about how to adapt existing clinical mitigation strategies to address immunogenicity. \nWith 35+ industry-based speakers covering pre-clinical and clinical immunogenicity challenges over 2 tracks and 3 packed days of content\, don’t miss your chance to join over 100+ fellow industry experts to network in person and share your research as you seek new and improved ways of predicting immunogenicity in the clinic to ultimately ensure the safety and efficacy of gene therapies. \nTo know more visit: https://ter.li/acp4lt
URL:https://www.pharmajournalist.com/event/3rd-annual-gene-therapy-immunogenicity-summit/
LOCATION:The Colonade\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221018
DTEND;VALUE=DATE:20221021
DTSTAMP:20260515T234014
CREATED:20220714T094650Z
LAST-MODIFIED:20220714T094650Z
UID:34667-1666051200-1666310399@www.pharmajournalist.com
SUMMARY:Operationalise: Early Access Programmes Summit Europe
DESCRIPTION:With over 100 early and managed access\, compassionate use\, and named patient programmes running across the continent\, the Operationalise: Early Access Programmes Summit Europe has been carefully curated to help you address difficulties with supply\, logistics and cost\, challenges with navigating European regulations\, and planning and running equitable\, patient-first early access programmes. \nDownload the full event guide to view the world-class speaker faculty of over 20 experienced EAP leaders\, who will be sharing their insights through best-practice case studies. \nImmerse yourself in three days of interactive sessions and discuss your peers’ approaches to involving the patient voice\, engaging different stakeholders\, planning considerations for a successful EAP and more. \nWith a specific focus on real-world case studies and practical applications\, join us to gain a greater understanding and clarity of the end-to-end management of running an early access programme in Europe.
URL:https://www.pharmajournalist.com/event/operationalise-early-access-programmes-summit-europe/
LOCATION:Hilton London Kensington\, 179-199 Holland Park Ave\, London\, W11 4UL\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221024
DTEND;VALUE=DATE:20221027
DTSTAMP:20260515T234014
CREATED:20220824T114426Z
LAST-MODIFIED:20220824T114426Z
UID:35001-1666569600-1666828799@www.pharmajournalist.com
SUMMARY:4th TIL Therapies Summit
DESCRIPTION:Commercialization looks set to propel TIL therapy into the spotlight for adoptive cell therapy\, and the 4th TIL Therapies Summit arrives to finally reunite the community in-person this October in Boston\, MA. \nFrom preclinical conversations to the latest developments in streamlined manufacturing this year’s meeting will be the most comprehensive guide for addressing the unique challenges of TIL development to bolster and strengthen your pipelines to achieve your 2022/23 milestones. \nWith 20+ world-class speakers and over 100 senior attendees from around the globe\, join the largest community of TIL-targeted drug development experts for a deep dive into clinical development progress\, lessons learnt and novel strategies to maximize TIL-targeting to recognize and capitalize on this outstanding approach in adoptive cell therapy! \nHere’s your exclusive snapshot of the world class speaker faculty: \n\nMichael Lotze\, Chief Cellular Therapy Officer\, Nurix Therapeutics\nMark Dudley\, Chief Scientific Officer\, InsTIL Bio\nDaniel J Powell Jr\, Associate Professor of Pathology and Laboratory Medicine\, University of Pennsylvania\nParameswaran Hari\, SVP Clinical Sciences\, Iovance Biotherapeutics\nNick Restifo\, Stealth Explorer\, Immunotherapy\nKarrie Wong\, Director Cell Therapy\, KSQ Therapeutics\nAndrew Weinberg\, Chief Scientific Officer\, AgonOx\nJan Ter Meulen\, Chief Scientific Officer\, Obsidian Therapeutics\nTom Henley\, Chief Scientific Officer\, Intima Biosciences\nStephanie Woodall\, Director – Head of Quality\, KSQ Therapeutics\nSylvia Lee\, Associate Professor\, Program in Immunology Clinical Research Division\, Fred Hutchinson Cancer Research Center\nUlrik Cordes\, Founder & Chief Executive Officer\, Cbio\n\nLearn from pioneering trailblazers in TIL development from the National Cancer Institute & University of Pennsylvania alongside leading industry representatives from the likes of Iovance\, Instil Bio and Obsidian Therapeutics. \nAs a host of developers look to bridge to the next generation of TIL therapies\, now is the time to leverage actionable insights to ensure you are set to capitalize on this achieve significant expansion in your development. \nJoin senior leaders from leading biotech\, clinical and academic institutes to discuss data-driven and solution-based approaches to supercharge your TIL therapy towards commercialization. \nTo know more visit: https://ter.li/ygtovu
URL:https://www.pharmajournalist.com/event/4th-til-therapies-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:https://ter.li/ygtovu
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221024
DTEND;VALUE=DATE:20221026
DTSTAMP:20260515T234014
CREATED:20220531T110715Z
LAST-MODIFIED:20220531T111046Z
UID:34316-1666569600-1666742399@www.pharmajournalist.com
SUMMARY:SAE Media Group’s 2nd Annual Biosensors for Medical Wearables
DESCRIPTION:SAE Media Group’s 2nd Annual Biosensors for Medical Wearables \n*In collaboration with Medical Design Briefs* \n24th – 25th October 2022 | Boston\, MA\, USA \nSponsored by: Raumedic \nhttp://www.biosensors-medical-wear.com/PJWL \nAdvances in development and therapeutic applications of on-body sensors \nSAE Media Group is proud to present the Biosensors for Medical Wearables Conference\, taking place on the 24th – 25th October 2022. \n \nAs part of SAE Media Group’s leading series of medical device conferences\, this year’s event will be exploring the key drivers and innovations of the wearable medical biosensors landscape with insights into the latest technologies uncovering the therapeutic scope of medical biosensors and the potential of wearable sensors for decentralized diagnostic testing. With growing digital application\, the 2022 agenda will also assess the potential of Artificial Intelligence coupled with sensors and understand how industry is managing digital outcomes. \nChairing the Conference this year will be industry giants James Mault\, MD\, Founder and CEO\, BioIntelliSense\, Inc and Andreas Caduff\, Strategic Advisory Board\, Digital Medicine Society (DiMe). \nThe featured 2022 speakers include: \n\nCarrie Northcott\, Director and Project Lead\, Digital Medicine\, and Translational Imaging (DMTI)\, Early Clinical Development (ECD)\, Pfizer\, Inc\nEric Richardson\, Vice President of Applied Research\, MedRhythms\, Inc.\nJennifer Goldsack\, CEO\, Digital Medicine Society (DiMe)\nSamir Shah\, Director\, AstraZeneca\nTero-Pekka Alastalo\, Chief Medical Officer and General Manager\, US Operations\, CardioSignal Inc\nJohn Ralston\, CEO and Founder\, Neursantys\, Inc.\nChristine Guo\, Chief Scientific c Officer\, ActiGraph\nXina Quan\, Co-Founder and CEO\, PyrAmes\, Inc.\nPierre-Alexandre Fournier\, Co-founder/CEO\, Hexoskin\n\nWhy should you attend? \n\nYou will explore the latest in biosensor technologies for wearable medical devices for therapeutics applications\nYou will uncover the potential of wearable sensors for decentralized diagnostic testing\nYou will delve into the evolving research and technologies to overcome unmet needs of the field including battery technologies for wearable sensors\nYou will assess the growing opportunities and sensor technologies being developed in industry for digital medicine and therapeutics\nYou will engage in platforms and opportunities for sensors coupled with AI and understand how industry are managing digital outcomes\n\nCheckout the early bird offers: \n\nBOOK BY 30TH JUNE AND SAVE $300\nBOOK BY 31ST AUGUST AND SAVE $200\n\nFor more information please contact: \nNikisha Galoria | Marketing Executive | SAE Media Group \nEmail: ngaloria@smi-online.co.uk \nPhone: +44 (0) 20 7827 6164 \nFollow us on: \nLinkedIn: SAE Media Group Pharma \nTwitter: @SAEMGPharma \n#MedicalWearables
URL:https://www.pharmajournalist.com/event/sae-media-groups-2nd-annual-biosensors-for-medical-wearables/
LOCATION:Boston\, MA\, USA
ORGANIZER;CN="SAE Media Group":MAILTO:ngaloria@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221025
DTEND;VALUE=DATE:20221028
DTSTAMP:20260515T234014
CREATED:20220708T072935Z
LAST-MODIFIED:20220708T072935Z
UID:34589-1666656000-1666915199@www.pharmajournalist.com
SUMMARY:6th Annual Gene Therapy for Rare Disorders Europe Summit 2022
DESCRIPTION:As more and more companies gear up for clinical activity and near approval decisions\, the need to have an in-depth understanding of the regulatory frameworks and how these feed into clinical development and manufacturing processes is as vital as ever. \nThis year’s summit is dedicated to gaining European regulatory clarity to progress efficient and robust gene therapies for rare diseases. By giving voice to pioneering drug developers with success stories to share\, experts in regulatory affairs\, and the regulators themselves\, this meeting is your comprehensive guide to unpicking the thorniest regulatory challenges. \nAcross three carefully curated days\, this streamlined one-track summit will unite key gene therapy leaders from large pharma to ground-breaking biotech\, academics to exciting service providers\, all with the purpose of paving a way forward to successfully launch gene therapy products in Europe. \nTo know more visit: https://bit.ly/3ysiVts
URL:https://www.pharmajournalist.com/event/6th-annual-gene-therapy-for-rare-disorders-europe-summit-2022/
LOCATION:London Marriott Hotel Regents Park\, 128 King Henry’s Road\, London\, NW3 3ST\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221025
DTEND;VALUE=DATE:20221028
DTSTAMP:20260515T234014
CREATED:20220801T092348Z
LAST-MODIFIED:20220801T092348Z
UID:34838-1666656000-1666915199@www.pharmajournalist.com
SUMMARY:7th Annual Computational Drug Development (CDD) for Biologics Summit
DESCRIPTION:Returning to Boston this October\, the 7th Annual Computational Drug Development (CDD) for Biologics Summit will continue to build on the reputation of past meetings while diving into the latest innovations in the industry. This year’s summit will highlight methods and best-practices to extrapolating data & leveraging deep learning for novel\, complex biologics pipeline progression.  \nAcross 3 days\, we will unite leading experts including AbbVie\, GSK\, Amgen\, Genentech\, Takeda & many more to: \n\nOvercome data availability and collection challenges to support machine learning and in silico drug discovery and development for biologics\nRefine high throughput screening methods for novel antibody candidates to shorten your drug development cycles\nAdvance the next generation of computational biology in designing complex antibodies – including multifunctional\, multi-specific antibodies\nEmpower the predictability of protein structures and protein-protein interactions for better drug development\nOptimize your development cycle and decision making using computational data\n\nFind out more – https://ter.li/ec2qbx
URL:https://www.pharmajournalist.com/event/7th-annual-computational-drug-development-cdd-for-biologics-summit/
LOCATION:Boston Marriott Burlington\, One Burlington Mall Road\, Burlington\, MA\, 01803\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221026
DTEND;VALUE=DATE:20221028
DTSTAMP:20260515T234014
CREATED:20220812T122604Z
LAST-MODIFIED:20220812T122604Z
UID:34912-1666742400-1666915199@www.pharmajournalist.com
SUMMARY:Protein Engineering Biocatalysis Congress
DESCRIPTION:The Protein Engineering Biocatalysis Congress is the unique meeting point of industry\, academia and service providers which will enable protein engineering and biocatalysis enthusiasts to industrialize sustainable enzyme products and increase product efficiency globally. \nThis event will highlight case studies on scaling up protein engineering technologies for commercial scale. It is your opportunity to analyze developments in protein engineering for biocatalysis to establish sustainable\, scalable and cost-efficient API manufacturing. \nTo know more visit: www.proteinengineeringglobal.com
URL:https://www.pharmajournalist.com/event/protein-engineering-biocatalysis-congress/
LOCATION:Philadelphia\, USA (venue TBC)
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221101
DTEND;VALUE=DATE:20221104
DTSTAMP:20260515T234014
CREATED:20220727T092002Z
LAST-MODIFIED:20220728T084955Z
UID:34790-1667260800-1667519999@www.pharmajournalist.com
SUMMARY:6th Dermatology Drug Development Summit
DESCRIPTION:The 6th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases returns to Boston this fall. \nEnsure you join this year’s 150+ expert community in-person to: \n\nUncover recent studies evaluating critical inflammatory and auto-immune pathways\nGain a deeper understanding of promising biologics targeting IL-13\, IL-31\, IL-33\, versus IL-17 associated diseases\nAssess emerging efficacious targeted approaches in the plethora of conditions outside of these pathways.\nObtain clarity on novel clinically validated endpoints within the regulatory landscape for critical dermatological conditions with high unmet needs such as Hidradenitis Suppurativa\, Vitiligo\, Rare Disease\, and Alopecia Areata\n\nView the event program here: https://ter.li/g3z67z \nRegister here: https://ter.li/vu3tx9 \nIf you have any further questions regarding the summit\, please contact us at info@hansonwade.com.
URL:https://www.pharmajournalist.com/event/6th-dermatology-drug-development-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221107
DTEND;VALUE=DATE:20221110
DTSTAMP:20260515T234014
CREATED:20220825T102329Z
LAST-MODIFIED:20220825T102329Z
UID:35008-1667779200-1668038399@www.pharmajournalist.com
SUMMARY:6th Microbiome Movement – Human Nutrition Summit
DESCRIPTION:Returning to Boston for 2022\, the 6th Microbiome Movement- Human Nutrition Summit is the only industry focused meeting dedicated to exploring the latest innovations\, practical applications and clinical benefits of microbiome targeting food\, beverages and supplements to pave the route to commercial success in the consumer health setting. \nGet up to speed on this dynamic industry with expertise shared from the likes of Bayer\, Postbiotics Plus\, Amazentis and many others\, as the titans of industry unite to: \n\nShowcase the latest scientific findings on the mechanism and functional role of novel microbiome targeting ingredients\nShine a spotlight on the future of postbiotics\, and advance commercialization of microbiome-targeted nutritional interventions\nAdvance commercialization of microbiome-targeted nutritional interventions\n\nWith consumers demanding to have greater control over personal health and wellbeing\, join your community of 100+ industry experts from global CPG companies\, innovative start-ups and biotechs to usher in a new wave of personalised nutrition. \nTo know more visit: https://bit.ly/3clIDZQ
URL:https://www.pharmajournalist.com/event/6th-microbiome-movement-human-nutrition-summit/
LOCATION:TBC
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221109
DTEND;VALUE=DATE:20221112
DTSTAMP:20260515T234014
CREATED:20220728T083732Z
LAST-MODIFIED:20220728T083732Z
UID:34796-1667952000-1668211199@www.pharmajournalist.com
SUMMARY:6th Antifibrotic Drug Development Summit (AFDD)
DESCRIPTION:Returning for the 6th year\, the Antifibrotic Drug Development Summit (AFDD) will host the transferrable insights you need from IPF\, NASH\, CKD and more in one place at one time\, so you can advance the progress of your antifibrotic therapies. \nFrom exploring cellular mechanisms to identify a common fibrotic pathway to bridging the translational gap to prove early therapeutic effectiveness; this unique cross-organ\, cross-disease\, cross-discipline discussion forum is here to transform your fibrosis research. \nJoin 100+ industry super giants from Boehringer Ingelheim\, Genentech\, Gilead\, Pfizer\, Novartis\, and many more in Boston to harness the knowledge you need for your 2022/23 antifibrotic research and drug development. \nTo know more visit: https://ter.li/u60ni5
URL:https://www.pharmajournalist.com/event/6th-antifibrotic-drug-development-summit-afdd/
LOCATION:Crowne Plaza Woburn\, 15 Middlesex Canal Park Rd\, Woburn\, MA\, 01801\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221114
DTEND;VALUE=DATE:20221116
DTSTAMP:20260515T234014
CREATED:20220609T062845Z
LAST-MODIFIED:20220609T062845Z
UID:34376-1668384000-1668556799@www.pharmajournalist.com
SUMMARY:Medical Devices and IVD 2022
DESCRIPTION:SAE Media Group’s Inaugural Conference… \nMedical Devices and IVD 2022\n14 – 15 November 2022\nLondon\, UK\nwww.medicaldevices-ivd.com/PJ \nNavigating The MDR and IVDR and Best Strategies for Compliance  \nSAE Media Group is proud to announce the launch of the Medical Devices and IVD Conference\, taking place on 14 – 15 November 2022 in London\, UK. \n \nThe MDR implementation last May has highlighted issues within the industry that need to be addressed and the upcoming IVDR updates will have a profound impact on the medical device industry\, bringing certain products into regulatory scope that were previously excluded\, introducing new manufacturing requirements\, and increasing the burden for post-market surveillance. \nThe conference will provide insight into the latest updates in EU MDR and IVDR regulations and will discuss strategies for how to best comply with these regulations. In addition\, the conference will consider the evolving regulatory landscape for digital health software. \nBENEFITS OF ATTENDING: \n\nEngage with notified body and competent authority representatives addressing key MDR and IVDR requirements\nGain insights from pharma regulatory experts in compliance and companion diagnostics\nUnderstand the latest guidance on IVD Regulations to overcome common challenges\, in addition to considering evolving global regulations\nExamine post-market expectations for surveillance and vigilance of your medical devices\nDelve into advancements in the digitalisation of medical devices and the regulatory considerations surrounding this\n\nWHO SHOULD ATTEND: \nExecutives\, Directors\, VPs\, Heads\, Principals\, Managers of: \n\nDevice Manufacturing\nRegulatory Affairs\nIVDR\nMDR\nCMC\nCompliance\nRisk Management\nTraceability\nVigilance\nProduct Development\nPFS\nCombination Products\n\nTo find out more\, please visit: www.medicaldevices-ivd.com/PJ \nEARLY BIRD RATES: \n\nBOOK BY 30TH JUNE TO SAVE £200\nBOOK BY 30TH SEPTEMBER TO SAVE £100\n\nADDITIONAL CONTACT INFORMATION: \n\nE: ngaloria@smi-online.co.uk\nT: +44 (0) 20 7827 6164\n\nFOLLOW US ON: \n\nTwitter: @SAEMGPharma\n\nLinkedIn: SAE Media Group Pharma
URL:https://www.pharmajournalist.com/event/medical-devices-and-ivd-2022/
LOCATION:London\, UK
ORGANIZER;CN="SAE Media Group":MAILTO:ngaloria@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221116
DTEND;VALUE=DATE:20221118
DTSTAMP:20260515T234014
CREATED:20220805T095510Z
LAST-MODIFIED:20220805T095849Z
UID:34850-1668556800-1668729599@www.pharmajournalist.com
SUMMARY:Microbiome Connect: USA 2022
DESCRIPTION:The 7th Annual Microbiome Connect: USA 2022 is dedicated to showcasing the leading drug development platforms applying microbes\, microbe modulators and microbial-derived components to prevent or treat human diseases or make medical diagnosis. As the first FDA approved microbiome-targeted therapeutic emerges\, drug developers will have the opportunity to benchmark their rational drug platforms\, targeting validated pathways in gastrointestinal\, neurological\, metabolic disorders\, as well as oncology-based indications. Furthermore\, the manufacturing challenges associated with reaching commercialization specific to microbiome-based drugs will be addressed in depth. With talks from Live Biotherapeutic Product manufacturing experts\, including the Head of CBER\, on topics including how to handle USP 61/62\, and achieving co-culturing capabilities. Join us to hear from microbiome biotechs\, pharma voices\, investment bodies\, and more on how to develop robust\, scalable\, and reproducible formulations for microbe-derived/-targeting products entering late-stage investigations and reaching for the market. \nTo know more visit: www.microbiomeconnectusa.com
URL:https://www.pharmajournalist.com/event/microbiome-connect-usa-2022/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221116
DTEND;VALUE=DATE:20221118
DTSTAMP:20260515T234014
CREATED:20221024T222603Z
LAST-MODIFIED:20221024T222746Z
UID:35596-1668556800-1668729599@www.pharmajournalist.com
SUMMARY:Liquid Biopsy Surveillance & Early Detection Summit
DESCRIPTION:Recognize Disease Hallmarks Earlier for Improved Patient Outcomes \nGain Clarity Across Next Generation Non-Invasive Testing Technologies Revolutionizing Cancer Monitoring\, MRD & Earlier Detection to Support Novel Pre-Metastatic Drug Development with Maximized Access \nIn the wake of new FDA guidance and exciting MRD partnership announcements between Grail & AstraZeneca\, Amgen & Bristol Myers Squibb the liquid biopsy industry is experiencing a paradigm shift. Touted as having the potential to transform clinical practice as we know it\, technical progress and mounting investment in premetastatic applications are creating huge industry-wide excitement for liquid biopsy-based screening & surveillance for novel precision drug development. \nWith technology maturity on the near horizon\, the inaugural Liquid Biopsy Surveillance & Early Detection Summit is your only dedicated platform providing much-needed clarity on the industry’s emerging assays increasingly opening the doors to novel trial design and better patient outcomes. \nAs drug & diagnostic developers look to realize the commercial impact of early detection & MRD while shifting pipelines from the metastatic setting\, here lies your best opportunity to harness game-changing technologies to define leading stratification\, surrogate endpoint\, and regulatory strategies – accelerating the delivery of breakthrough therapies into the clinic. \nProviding a path forward for early detection & surveillance to become a widespread patient reality\, unite with 80+ Translational\, Biomarker\, Clinical\, Regulatory\, Precision Medicine\, Medical Affairs & Diagnostic experts at your only forum prioritizing liquid biopsy applications for earlier intervention. \nTo know more visit: https://ter.li/0kjtfi
URL:https://www.pharmajournalist.com/event/liquid-biopsy-surveillance-early-detection-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221128
DTEND;VALUE=DATE:20221202
DTSTAMP:20260515T234014
CREATED:20220720T112134Z
LAST-MODIFIED:20220720T112134Z
UID:34732-1669593600-1669939199@www.pharmajournalist.com
SUMMARY:4th Annual Gene Therapy Analytical Development Summit 2022
DESCRIPTION:The past twelve months have culminated in an unprecedented level of excitement\, investment\, and clinical progress within the gene therapy field. As the field strives to strike a delicate balance between safety and efficacy\, in the context of increased regulatory scrutiny and safety challenges\, attending the 4th Annual Gene Therapy Analytical Development as an analytical scientist has never been so important. \nThis year’s summit returns in-person to Boston to reunite 300+ analytical experts in innovative biotech\, pharma and academia to continue to develop resilient\, long-lasting and robust analytical tools to enhance the safety\, quality and efficacy of gene therapy products.   \nWhether you are focusing on specific characterization methods\, enhancing your genome sequencing\, advancing your understanding of full and partial particles\, or advancing your early-stage bioassays\, with 4 tracks\, 8 pre-conference workshops and a post-conference focus day\, the 4th Gene Therapy Analytical Development Summit will encompass all aspects of analytical development\, giving you the chance to address and overcome challenges. \nIf you work in quality control\, quality assurance\, or process development – we’ve listened and we’ve answered. This year’s agenda includes a novel track designed for quality control and process development groups working in gene therapy. Talks include enhancing the knowledge transfer between departments\, bridging between analytical methods with regards to QC/PD\, and enhancing in-process development support. \nWhether you’re working with AAV\, non-viral vectors or lentiviral vectors\, this is your opportunity to enhance your existing analytical methods and explore innovative new tools to support safe and effective gene therapy development. \nTo know more visit: https://ter.li/w2diiu
URL:https://www.pharmajournalist.com/event/4th-annual-gene-therapy-analytical-development-summit-2022/
LOCATION:Westin Boston Seaport\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221128
DTEND;VALUE=DATE:20221201
DTSTAMP:20260515T234014
CREATED:20220819T112405Z
LAST-MODIFIED:20220819T112405Z
UID:34933-1669593600-1669852799@www.pharmajournalist.com
SUMMARY:2nd Rare CNS & Neurodevelopmental Drug Development Summit
DESCRIPTION:Developing New Outcome Measures\, Functional Biomarkers & Clinical Research Regulatory Frameworks for Disease-Modifying Therapeutics Across Neurodevelopmental & Rare\, Genetic CNS Disorders \nWith more clinical data emerging\, neurodevelopmental drug development is advancing from hypotheticals to real-life clinical results\, outcomes\, and functional biomarkers\, catapulting this critical field forwards. \nJoin 100+ peers this November at the 2nd Rare CNS & Neurodevelopmental Drug Development Summit – the only industry dedicated drug development forum for large pharma\, biotech\, academia\, and patient advocacy groups\, paving the way towards symptomatic and successful disease modifying treatments. \nTightly focused on industry progress\, stakeholders will explore ASOs\, gene therapies and small molecules across autistic syndromes and seizure phenotypes at this unique drug sponsor conference. \nDon’t miss out on this definitive opportunity to collaborate with patient groups and gain regulatory clarity on clinical trial design\, endpoints and delivery and toxicity concerns as well as deep diving into functional and molecular biomarkers\, emerging therapeutic targets and translational biology. \nIf you are working towards treatments for rare CNS and neurodevelopmental disorders\, including (but not limited to) Angelman Syndrome\, Rett syndrome\, Fragile X\, Dravet Syndrome and CDKL5 Syndrome or discovering new frontiers in anti-epileptic therapeutics\, this is the platform you need. \nTo know more visit: https://ter.li/9yzux5
URL:https://www.pharmajournalist.com/event/2nd-rare-cns-neurodevelopmental-drug-development-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221129
DTEND;VALUE=DATE:20221202
DTSTAMP:20260515T234014
CREATED:20220811T093237Z
LAST-MODIFIED:20220811T093237Z
UID:34895-1669680000-1669939199@www.pharmajournalist.com
SUMMARY:4th Inflammasome Therapeutics Summit
DESCRIPTION:The 4th Inflammasome Therapeutics Summit is the only industry-led forum uniting large pharma\, biotechs\, and academic KOLs\, with the common goal of accelerating the practical translation and clinical development of inflammasome-targeted drugs\, which are shaking up the immunology R&D landscape. \nAs the space eagerly awaits data readouts from proof-of-concept trials\, and with more companies than ever before with active inflammasome therapeutic pipelines; this is your opportunity to be involved in interactive discussions on: \n\nDeciphering the intricate mechanisms underlying dysregulated inflammasome signaling within the wider context of the immune system \nOvercoming limitations of preclinical models\, identifying clinically meaningful biomarkers of inflammasome inhibition\, and defining good clinical endpoints \nTaming inflammation and achieving optimized safety profiles using the next frontier for inflammasome-targeted drugs including those targeting NLRP3 and novel targets \nDelving into specific disease groups to demonstrate where inflammasome therapeutics will be most impactful\n\nJoin 120+ fellow peers and industry heavyweights this Fall including NodThera\, Novartis\, Zyversa Therapeutics\, and more\, to build meaningful partnerships and propel the next frontier of inflammasome therapeutics from pipeline development into a clinical and commercial reality. \nAccess the official event guide here to learn more.
URL:https://www.pharmajournalist.com/event/4th-inflammasome-therapeutics-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221129
DTEND;VALUE=DATE:20221202
DTSTAMP:20260515T234014
CREATED:20220811T093818Z
LAST-MODIFIED:20220815T091224Z
UID:34899-1669680000-1669939199@www.pharmajournalist.com
SUMMARY:6th Obesity & NASH Drug Development Summit
DESCRIPTION:The first wave of investment in NASH is dispersing in the wake of highly demanding biopsy endpoints\, but opportunities to target obesity and metabolic syndrome are catalyzing increasing excitement. Pivotal readouts in GLP-1 receptor agonists and exciting progress in regenerative medicine and microRNAs are redefining the drug development landscape for metabolic disorders. \n \nWith mounting competition for the market in obesity and all eyes on the next wave of NASH candidates\, the 6th Obesity & NASH Drug Development Summit\, (previously the NASH Summit) is dedicated to reuniting industry leaders in metabolic syndrome to consolidate targets directly implicated in disease pathology and traverse the regulatory hurdles to commercialization. \nJoin 150+ industry pioneers in Boston including pioneers Novo Nordisk\, Eli Lilly\, Boehringer Ingelheim\, Pfizer\, Inventiva\, Regeneron\, FDA\, AstraZeneca\, and more to advance your pipeline towards approved treatment. \nAccess the official event guide here to learn more.
URL:https://www.pharmajournalist.com/event/6th-obesity-nash-drug-development-summit/
LOCATION:Revere Boston Common\, 200 Stuart St\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221129
DTEND;VALUE=DATE:20221202
DTSTAMP:20260515T234014
CREATED:20220824T095329Z
LAST-MODIFIED:20220824T114844Z
UID:34996-1669680000-1669939199@www.pharmajournalist.com
SUMMARY:3rd CRISPR 2.0 Summit
DESCRIPTION:Recognized with a Nobel Prize in 2020\, CRISPR has opened the floodgates for a new era of gene editing therapies\, promising to transform genetic disease treatments. With a well-established early field of genomics research\, drug developers and researchers have been busy establishing the next-generation CRISPR toolkit\, including Cas nucleases\, base and prime editing technologies\, and innovative delivery platforms. \nThe 3rd CRISPR 2.0 Summit is devoted to showcasing the latest and greatest innovations by uncovering how the next generation of CRISPR tools are radically enhancing efficacy\, minimizing off-target effects & enabling efficient tissue-specific delivery to help you progress your program into and through the clinic. \nAcross three days of content\, co-designed with 27+ industry thought leaders\, this streamlined one-track summit will unite 100+ key players in the CRISPR space\, from large pharma to ground-breaking biotech\, academics to exciting service providers\, all with the purpose of paving a way forward to market for your CRISPR gene editing program. \nHere’s a snapshot of our 27+ thought leaders: \n\nKiran Musunuru\, Professor of Medicine\, Perelman School of Medicine\, University of Pennsylvania\nAmy Simon\, Chief Medical Officer\, Beam Therapeutics\nJane Grogan\, Chief Scientific Officer\, Graphite Bio\nLiron Walsh\, Head of Development; In Vivo Programs\, Intellia Therapeutics\nJeremy Duffield\, Chief Scientific Officer\, Prime Medicine\nEric B. Kmiec\, Executive Director & Chief Scientific Officer\, Christiana Care Gene Editing Institute\nRafi Emmanuel\, Senior Vice President – Research & Development\, Emendo Biotherapeutics\nJohn Murphy\, Chief Scientific Officer\, Arbor Biotechnologies\nInge Yung-Chih Cheng\, Principal Scientist\, Pfizer\nJoey Riepsaame\, Head of Genome Engineering\, University of Oxford\nRammohan Devulapally\, Principal Scientist\, GenEdit\n\nBe part of the community as we dive deep into: \n\nRefining non-viral tissue targeted CRISPR delivery methods for maximized safety and efficacy\, with help from GenEdit and the latest research from the David Liu Lab.\nFrom bench to bedside: translating basic CRISPR research into a viable therapeutic product\, with Beam Therapeutics\nLeverage the latest base and prime editing technology for enhanced precision treatment of inherited disorders\, with Prime Medicine and UC Irvine.\n\nAnd more! \nJoin this unmissable summit and network experts from the likes of Beam Therapeutics\, The David Liu Lab\, Pfizer\, GenEdit\, AZ\, GSK\, Caribou Biosciences\, Prime Medicine\, Intellia Therapeutics and many more. \nTo know more visit: https://ter.li/vumobp
URL:https://www.pharmajournalist.com/event/3rd-crispr-2-0-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221201
DTEND;VALUE=DATE:20221203
DTSTAMP:20260515T234014
CREATED:20220923T091314Z
LAST-MODIFIED:20220923T091314Z
UID:35230-1669852800-1670025599@www.pharmajournalist.com
SUMMARY:PAT & Real Time Quality Summit
DESCRIPTION:The time has come to remove the pharmaceutical industry’s reliance on archaic off-line testing and embrace the cost and speed-to-market savings of online control and real-time product quality. \nThe PAT market is projected to reach USD 4.96 Billion by 2027\, spurred on by the recent ICH Q14/ Q2 (R2) guidelines\, there has never been a more opportune moment to leverage regulator’s support of QbD\, real-time control\, and process intervention to achieve meaningful business impact in your organization\, through reduced downtime\, manufacturing footprint\, ease of scale-up and product consistency for approval. \nWhether you’re applying in small molecules\, biologics\, or ATMP\, bridge the gap in technology\, culture\, or regulatory experience that is the bottleneck to your organization saving an average 50% reduction in process cycle time and winning speed to market\, with the strategical implementation of smart process analytical technologies and quality by control (QbC). \nJoin a senior community of experts in process development\, manufacturing\, regulatory & quality to understand how to monitor critical quality attributes with reactive and predictive control systems and discover novel PAT technologies as the industry moves the needle toward realizing real-time release. \nTo know more visit: https://ter.li/080rbc
URL:https://www.pharmajournalist.com/event/pat-real-time-quality-summit/
LOCATION:Hilton San Diego Gaslamp Quarter\, 401 K Street\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221205
DTEND;VALUE=DATE:20221209
DTSTAMP:20260515T234014
CREATED:20220819T112000Z
LAST-MODIFIED:20220819T112000Z
UID:34927-1670198400-1670543999@www.pharmajournalist.com
SUMMARY:4th Annual Gene Therapy for Neurological Disorders
DESCRIPTION:Delivering the Next Wave of Gene Therapies to the CNS \nWith systemic toxicity challenges plaguing the AAV field\, direct administration for CNS indications creates an ideal target for gene therapy. This is an exciting year for the neurological space with clinical data to show and new biotechs coming out of the woodwork to release the next wave of gene therapies with more advanced CNS targeting for a wider selection of neurological targets. \nThe 4th Annual Gene Therapy for Neurological Disorders Summit will unite gene therapy developers with an industry-focused agenda across 4 days and 2 dedicated tracks of content to solve the preclinical\, translational and clinical challenges of targeting a wide range of neurodevelopmental and neurodegenerative disorders with both ‘first’ and ‘next’ generation gene therapies. \nJoin the expanding audience of gene therapy experts to: \n\nStreamline CNS drug delivery devices for improved brain biodistribution\nDiscover novel vectors for CNS specificity & tropism\nOptimize gene therapy strategy for pediatric & adult neurological disorders\n\nTo know more visit: https://ter.li/rluqrj
URL:https://www.pharmajournalist.com/event/4th-annual-gene-therapy-for-neurological-disorders/
LOCATION:The Westin Seaport District\, 425 Summer St\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221205
DTEND;VALUE=DATE:20221208
DTSTAMP:20260515T234014
CREATED:20220919T115535Z
LAST-MODIFIED:20220919T115535Z
UID:35224-1670198400-1670457599@www.pharmajournalist.com
SUMMARY:4th Annual Cell Therapy Analytical Development Summit
DESCRIPTION:Cell Therapy Analytical Development Summit US is back for its fourth year\, taking place in Boston (December 5-7). Join 180+ colleagues from analytical development\, process development\, quality control and regulatory affairs\, to standardize analytical testing and take advantage of unrivalled content across: \n\n3-days\n6 deep-dive workshops\n2 tracks\n\nSeize an unmatched opportunity to delve into cell potency\, safety\, viability\, sterility and more across both autologous and allogeneic cell therapy products. \nPlease use this URL – https://ter.li/ghwxjk
URL:https://www.pharmajournalist.com/event/4th-annual-cell-therapy-analytical-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221206
DTEND;VALUE=DATE:20221209
DTSTAMP:20260515T234014
CREATED:20220914T121744Z
LAST-MODIFIED:20220914T121744Z
UID:35170-1670284800-1670543999@www.pharmajournalist.com
SUMMARY:5th Commercializing Clinically Validated Digital Therapeutics Summit
DESCRIPTION:The 5th Commercializing Clinically Validated Digital Therapeutics Summit\, designed with DTx companies\, pharma and clinicians\, will return this December to address the industry’s major challenges such as improving user experience\, clinical trial development\, and standing out in a crowded market through open discussion and case-study led presentations.   \nWhether you’re a veteran at commercializing clinically validated digital therapeutics\, looking for partnerships\, or a new entrant to the field\, you’ll leave this conference with practical lessons and essential connections needed to supercharge DTx commercial ambitions across 2022 and beyond. \nTo know more visit: https://ter.li/5e6hqd
URL:https://www.pharmajournalist.com/event/5th-commercializing-clinically-validated-digital-therapeutics-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221206
DTEND;VALUE=DATE:20221209
DTSTAMP:20260515T234014
CREATED:20221024T225543Z
LAST-MODIFIED:20221025T102843Z
UID:35606-1670284800-1670543999@www.pharmajournalist.com
SUMMARY:4th Annual Targeted Radiopharmaceuticals Summit Europe
DESCRIPTION:The long-awaited 4th Annual Targeted Radiopharmaceuticals Summit Europe is returning in-person in Amsterdam on December 6-8\, 2022! \nAs the only devoted meeting for large pharma\, biotech and pioneering academics\, this meeting unites key stakeholders under the mutual and ambitious objective of advancing radioligand candidates to commercialisation through rigorous clinical rationale and reliable supply chain design. \nDownload the full Event Guide to learn what the 29+ expert speakers will present on\, including: \n\n\n\nMeeting the newest contenders to enter the field including Ariceum Therapeutics and TRIMT\nDiscovering new targeting systems that are opening avenues to treating more cancers with Tagworks and Ratio Therapeutics\nGetting the most up-to-date information on current radionuclide stocks and how the world’s leading isotope producers are increasing their production and variety of products with Duke University\nEnhancing your trial design to conduct the most rigorous trials with help from leading clinical stage companies with Oncoinvent\nThe ability to showcase your work and meet new people across dedicated sessions and have the meetings that will help you build vital collaborations\n\n\n\nAccess the official Event Guide here to see the complete agenda and speaker line up.
URL:https://www.pharmajournalist.com/event/4th-annual-targeted-radiopharmaceuticals-summit-europe/
LOCATION:Leonardo Royal Amsterdam\, Paul van Vlissingenstraat 24\, Amsterdam\, 1096 BK\, Netherlands
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221206
DTEND;VALUE=DATE:20221208
DTSTAMP:20260515T234014
CREATED:20221110T115946Z
LAST-MODIFIED:20221110T115946Z
UID:35768-1670284800-1670457599@www.pharmajournalist.com
SUMMARY:2nd Next-Generation Food Allergy Drug Development Summit
DESCRIPTION:The field of food allergy therapeutics is continuing to boom as companies flood the news with fresh IND clearances and clinical readouts. The race to market for the next food allergy therapy is well and truly on\, but access to funding and large patient cohorts\, along with the need for novel IgE biomarkers and better diagnostics (to name a few challenges) are holding drug developers back from even faster progress. \nThe 2nd Next-Generation Food Allergy Drug Development Summit is reuniting this December as the only industry-focused meeting dedicated to unveiling the complexities of food allergies with novel oral immunotherapies\, antibody-based therapeutics and microbiome-based approaches to accelerate ground-breaking treatments for the ever-increasing unmet medical need. \nJoin us in-person for the first time in Boston as the food allergy community comes together to unravel the complex regulatory landscape\, identify and validate novel clinical biomarkers to aid patient selection and explore novel routes of administration to innovate long-lasting\, next-generation treatments. \nTo know more visit: https://bit.ly/3GlzzRp
URL:https://www.pharmajournalist.com/event/2nd-next-generation-food-allergy-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221207
DTEND;VALUE=DATE:20221209
DTSTAMP:20260515T234014
CREATED:20220727T082442Z
LAST-MODIFIED:20220727T082442Z
UID:34784-1670371200-1670543999@www.pharmajournalist.com
SUMMARY:3rd TIGIT Axis Therapies Summit
DESCRIPTION:In the context of a need to regroup and accelerate practice-changing cancer immunotherapies towards approval and to patients in need\, the 3rd TIGIT Axis Therapies Summit returns to reunite large pharma\, innovative biotechs and pioneering academics to discuss the full range of next-generation TIGIT axis targeted drug modalities and maximize TIGIT-axis targeting in the solid tumor\, blood cancer and non-oncology setting. \nCovering deciphering the mechanistic intricacies underlying TIGIT axis signaling\, defining combination partners that improve efficacy and strengthen TIGIT targeted pipelines\, exploring novel drug designs in terms of Fc functionality and IgG type\, identifying molecular signatures relevant to the tumor microenvironment and periphery to incorporating unique pharmacology properties into trial design\, this is your comprehensive guide for addressing the unique challenges of TIGIT axis targeted drug development and powering up your pipelines. \nThis year’s sharp two-day agenda leans into the clinical headwinds faced by so many immune checkpoint targets. As the space regroups\, join the conversation to build meaningful partnerships and maximize the clinical and commercial success of the next generation of TIGIT axis targeted drugs. \nFind out more here: https://ter.li/ir0syg
URL:https://www.pharmajournalist.com/event/3rd-tigit-axis-therapies-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221213
DTEND;VALUE=DATE:20221216
DTSTAMP:20260515T234014
CREATED:20220728T084521Z
LAST-MODIFIED:20220728T084521Z
UID:34801-1670889600-1671148799@www.pharmajournalist.com
SUMMARY:5th Annual RNA-Targeted Drug Discovery Summit
DESCRIPTION:RNA-Targeted Drug Discovery Summit returns for its fifth year this December. Join the summit for deep dive into new and emerging topics such as: \n\nInduced Proximity as a new class of “targeted RNA degraders”\nNext-generation probing and screening technologies to accelerate HIT identification and validation\nBiophysical\, biochemical\, and cell-based assay development strategies to identify and optimize small molecules interacting with RNA\nIn vivo pharmacology\, safety\, and efficacy early considerations to accelerate the transition from discovery to pre-clinical and clinical development\n\nView the event program here: https://ter.li/7qs017 \nSecure your place here: https://ter.li/jlh128 \nIf you have any further questions regarding the summit\, please contact us at info@hansonwade.com.
URL:https://www.pharmajournalist.com/event/5th-annual-rna-targeted-drug-discovery-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221213
DTEND;VALUE=DATE:20221216
DTSTAMP:20260515T234014
CREATED:20220822T112559Z
LAST-MODIFIED:20221018T100720Z
UID:34982-1670889600-1671148799@www.pharmajournalist.com
SUMMARY:2nd Synthetic Biology-Based Therapies Summit
DESCRIPTION:Returning for a second year the Synthetic Biology-Based Therapies Summit is the leading industry-defining forum made exclusively for leaders in the synthetic and engineered biology space\, focusing on the technical challenges that lie ahead in the path towards commercialization. \nDownload the event guide to find out more \nLearn from industry trailblazers at Arsenal Biosciences\, bit.bio\, Moderna\, MIT\, Novome Bio\, Strand Therapeutics\, Synlogic and more\, to support your efforts in developing safe and effective synthetic biology-based therapeutics. \nJoin Global Innovators to: \n\nLearn from the academics that are driving the future of synthetic biology development with the National Institute of Standards & Technology and Massachusetts Institute of Technology\nLeverage novel control strategies for improved therapeutic efficacy and patient safety with Arsenal Biosciences\, bit.bio\, CHAIN Biotechnology and Strand Therapeutics\nEmploy synthetic biology techniques in the clinic\, hearing about a variety of therapeutic applications with Kite Pharma: A Gilead Company\, Novome Biotechnologies and Senti Biosciences\nApply computation\, artificial intelligence\, and machine learning to engineered and synthetic biology with Lawrence Berkley National Laboratory and Sanofi\nExplore the potential for engineered biology as a tool for drug discovery and development with LifeMine Therapeutics and Merck & Co.
URL:https://www.pharmajournalist.com/event/2nd-synthetic-biology-based-therapies-summit/
LOCATION:(exact venue TBC)\, Boston\, US.
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221213
DTEND;VALUE=DATE:20221215
DTSTAMP:20260515T234014
CREATED:20220909T103058Z
LAST-MODIFIED:20220909T103058Z
UID:35114-1670889600-1671062399@www.pharmajournalist.com
SUMMARY:Advanced Wound Care Summit Europe 2022
DESCRIPTION:The Advanced Wound Care Summit EU is the first industry-led\, EU-focused\, forum on commercialising innovative wound care products. How will you comply with the EU MDR? What is the best strategy to ensure widespread clinical adoption and reimbursement? What can you do to engage with other wound care companies\, for collaboration or acquisition? Expect to hear from\, and network with\, wound care leaders\, across large wound care companies and SMEs. \nFind out how C-level Executives\, VPs and Directors of R&D are tackling the most pressing industry challenges\, seizing growth opportunities\, and building innovation. Whether an executive\, investor\, researcher or healthcare professional\, this meeting offers an empowering environment that allows you to secure your stake in the AWC market. \nTo know more visit: https://hubs.ly/Q01lR8NX0
URL:https://www.pharmajournalist.com/event/advanced-wound-care-summit-europe-2022/
LOCATION:TBC\, Berlin\, Germany
ORGANIZER;CN="Kisaco Research":MAILTO:Jodie.purser@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221214
DTEND;VALUE=DATE:20221215
DTSTAMP:20260515T234014
CREATED:20221018T101336Z
LAST-MODIFIED:20221018T105122Z
UID:35527-1670976000-1671062399@www.pharmajournalist.com
SUMMARY:PURIFY – Chromatography Purification Conclave
DESCRIPTION:PURIFY Conclaves are pioneers of dedicated conferences in India that will help stretch possibilities\, be it discovery\, development or scaleups! \nThe pharmaceutical industry continues to dwell deeper into the growing possibilities for chromatography purification; the PURIFY conclaves touches upon diverse aspects of chromatography purification. \nThe attendees at PURIFY get exposed to a myriad of topics that could change the way they work…change the way they purify. New separation techniques and approaches\, niche topics\, deeper understanding of preparative and process chromatography and allied fields\, and upcoming application areas that will provide quality substance to the discerning scientists. So\, if you wish to get that additional gram\, which is purer\, in as less a time\, with minimal resources…there will surely be something for you at PURIFY conclaves! \nThe annually occurring PURIFY Conclave is an initiative by Custage Marketing Solutions LLP\, a Mumbai based company. \nThe PURIFY conclave is attended by analytical and research chemists\, scientists with scale-up and process development knowledge\, managers\, group heads\, natural product purification experts\, experts from quality and manufacturing\, academicians\, policy makers\, supply chain heads etc. of this pharmaceutical – APIs\, peptides\, proteins\, oligonucleotides\, chiral molecules\, bio-pharmaceutical\, fine chemicals\, environmental studies\, food and beverage\, polymers\, biotechnology\, cosmetics and fragrance to understand the advancements in chromatography platforms. \nSo\, the purification expert in you will surely get answers to the daily challenges faced for you in your laboratories. And what’s more\, the knowledge comes to you from dignitaries who are institutions on their own in chromatography purification and related.
URL:https://www.pharmajournalist.com/event/purify-chromatography-purification-conclave/
LOCATION:Taj Skyline\, Ahmedabad
ORGANIZER;CN="Custage Marketing Solutions LLP":MAILTO:rashi@custage.com
END:VEVENT
END:VCALENDAR